KRAS and neoplasm: While foundational methods like Sanger sequencing laid the groundwork for KRAS analysis, their clinical utility has dwindled in the precision medicine era due to inherent limitations in their sensitivity, particularly in mixed tumor samples or degraded specimens [90,182,183,184].